Skip to main content
BOTANIX PHARMACEUTICALS LTD logo

BOTANIX PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · BOT ISIN · AU000000BOT2 ASX Manufacturing
Open in API
Filings indexed 1,209 across all filing types
Latest filing 2020-10-12 Interim / Quarterly Rep…
Country AU Australia
Listing ASX BOT

About BOTANIX PHARMACEUTICALS LTD

https://botanixpharma.com/

Botanix Pharmaceuticals Ltd is a clinical-stage pharmaceutical company focused on the development and commercialization of novel topical treatments for serious skin conditions. The company utilizes its proprietary Permetrex™ skin delivery technology, which is designed to improve the delivery of active ingredients through the skin. Its primary product, Sofdra™ (sofpironium bromide), is an FDA-approved prescription topical gel for the treatment of primary axillary hyperhidrosis. The company's research and development pipeline also includes clinical-stage candidates for the treatment of acne, rosacea, and atopic dermatitis. Botanix aims to address significant unmet medical needs in dermatology by providing innovative therapeutic solutions with enhanced safety and efficacy profiles.

Recent filings

Filing Released Lang Actions
Appendix 4C - Quarterly 9 pages 366.0KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Botanix Pharmaceuticals Quarterly Activities Report and 4C Quarterly Cash Flow Report' and is dated 13 October 2020. It contains detailed information about clinical development progress, financial position including cash flows, and corporate updates for the quarter ended 30 September 2020. The presence of the Appendix 4C Quarterly Cash Flow report, which is a regulatory requirement for quarterly reporting in Australia, confirms this is a quarterly financial and operational report. The document includes substantive financial data such as cash flows from operating, investing, and financing activities, as well as narrative on business activities and clinical progress. It is not merely an announcement or a brief summary but a comprehensive quarterly report. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2020-10-12 English
Response to ASX Price Query 4 pages 726.6KB
Regulatory Filings Classification · 100% confidence The document is a letter from ASX Compliance to Botanix Pharmaceuticals Ltd regarding a price query about unusual trading activity in the company's securities. It requests information about any undisclosed material information and compliance with listing rules, specifically Listing Rule 3.1 and 3.1A. The document is a regulatory inquiry and response letter, not a financial report, earnings release, or any other type of corporate filing. It is a compliance communication related to continuous disclosure obligations under stock exchange rules. The document length is 6154 characters, which is relatively short and contains no financial data or report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2020-09-28 English
Annual Report to Shareholders with Revised Top 20 71 pages 929.3KB
Annual Report Classification · 100% confidence The document is titled 'ANNUAL REPORT for the year ended 30 June 2020' and contains detailed sections typical of an annual report, including Directors' Report, Auditor's Independence Declaration, Consolidated Financial Statements, Notes to the Financial Statements, Directors' Declaration, Independent Auditor's Report, and Corporate Governance Statement. The content includes comprehensive financial data, management discussion, and corporate information. The document length is 15,000 characters, indicating it is a full report rather than a brief announcement. There is no indication that this is merely an announcement of the report or a certification letter. Therefore, this document fits the definition of an Annual Report (10-K).
2020-09-07 English
New Antimicrobial Data and Conference Presentation 20 pages 1.8MB
Investor Presentation Classification · 95% confidence The document is a detailed investor presentation dated 8 September 2020 from Botanix Pharmaceuticals. It includes new antimicrobial data, clinical study updates, and scientific explanations of their product BTX 1801. The text references a conference presentation at the 2020 ASX Small & Mid-Cap Virtual Conference and mentions that the presentation is attached to the release. The content is focused on scientific data, clinical pipeline, and company strategy rather than financial results or regulatory filings. It is not a full annual or interim report, nor an earnings release. It is not a regulatory filing or announcement of voting results. The document is a detailed presentation aimed at investors, covering financials, strategy, and market position, consistent with the definition of an Investor Presentation (IP). The length (15,000 characters) and detailed content support this classification with high confidence.
2020-09-07 English
Appendix 4E and Annual Report to Shareholders 73 pages 1.1MB
Annual Report Classification · 100% confidence The document is titled 'Appendix 4E Final report' and includes detailed financial data for the year ended 30 June 2020, including profit and loss, net tangible assets, dividends, and a comprehensive Directors' Report. It also references the Annual Report for the year ended 30 June 2020, with detailed contents such as financial statements, auditor's report, and corporate governance statement. The document is lengthy (15,000 characters) and contains substantive financial data and management discussion. It is not merely an announcement or a certification but a full financial report. The presence of detailed financial statements and directors' report aligns with the characteristics of an Annual Report (10-K equivalent). Therefore, the document should be classified as an Annual Report (10-K).
2020-08-30 English
Appendix 4G 11 pages 187.5KB
Regulatory Filings
2020-08-30 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.